

ETHIOPIA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Ethiopia					
2. Grant number: 1820-ETH-12a-X /10-ETH-08b-Y					
3. Date of Decision Letter: 23 March 2018					
4. Date of the Partnership Framework Agreement: 23 July 2013					
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine					
6. Vaccine type: Pneumococcal					
7. Requested product presentation and formulation of vaccine: PCV10, 2 doses/vial, liq					
8. Programme duration¹: 2011 - 2020					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2011-2017	2018	2019	2020	Total ²
Programme Budget (US\$)	295,216,411 ³	14,429,500	34,266,500	36,819,000	380,731,411
10. Vaccine introduction grant (in US\$): A VIG of US\$881,500 was disbursed on 11 October 2011.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2011-2017	2018			
Number of Pneumococcal vaccines doses		4,297,600			
Annual Amounts (US\$)	US\$295,216,411 ⁵	US\$14,429,500			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1820-ETH-12a-X-C</p> <p>According to the co-financing policy, the country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>									
Type of supplies to be purchased with Country funds in each year	2018	2019	2020						
Number of vaccine doses	300,000	683,600	708,400						
Value of vaccine doses (US\$)	US\$914,004	US\$2,084,221	US\$2,160,163						
Total co-financing payments (US\$) (including freight)	US\$920,000	US\$2,097,000	US\$2,173,500						
<p>15. Operational support for campaigns: Not applicable</p>									
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>				Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
<p>17. Financial clarifications: Not applicable</p>									
<p>18. Other conditions: Not applicable</p>									

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
23 March 2018